



Antibodies

1P-404-C100

## Monoclonal Antibody to CD358 / DR6 Phycoerythrin (PE) conjugated (0.1 mg)

<b>Clone:</b>	DR-6-04-EC
<b>Isotype:</b>	Mouse IgG1
<b>Specificity:</b>	The antibody DR-6-04-EC recognizes human DR6 (Death receptor-6), a type I transmembrane protein containing cytoplasmic death domain, widely expressed in most human tissues and cell lines.
<b>Immunogen:</b>	A fusion protein representing amino acids 42-335 (extracellular part) of human DR6 linked to the Fc portion of human IgG1 was used as an immunogen.
<b>Species Reactivity:</b>	Human
<b>Preparation:</b>	The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
<b>Concentration:</b>	0.1 mg/ml
<b>Storage Buffer:</b>	The reagent is provided in phosphate buffered saline (PBS) containing 15 mM sodium azide and 0.2% (w/v) high-grade protease free Bovine Serum Albumin (BSA) as a stabilizing agent.
<b>Storage / Stability:</b>	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label. Short-term exposure to room temperature should not affect the quality of the reagent. However, if reagent is stored under any conditions other than those specified, the conditions must be verified by the user.
<b>Usage:</b>	The reagent is designed for Flow Cytometry analysis. Suggested working dilution is 10 µg/ml. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.
<b>Expiration:</b>	See vial label
<b>Lot Number:</b>	See vial label
<b>Background:</b>	CD358 / DR6 (Death Receptor-6) is a type I transmembrane protein of the TNF receptor superfamily, expressed in most human tissues and able of inducing apoptosis through its cytoplasmic death domain. Unlike TNFR1 and Fas, DR6 induces apoptosis independently of FADD adaptor. In immune system, DR6 serves as an important regulator for CD4+ T cell proliferation and Th differentiation, and provides also a regulatory mechanism for B cell activation and humoral immune responses.

**For laboratory research only, not for drug, diagnostic or other use.**



**Antibodies**

**References:**

- \*Pan G, Bauer JH, Haridas V, Wang S, Liu D, Yu G, Vincenz C, Aggarwal BB, Ni J, Dixit VM: Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. *FEBS Lett.* 1998 Jul 24;431(3):351-6.
- \*Kasof GM, Lu JJ, Liu D, Speer B, Mongan KN, Gomes BC, Lorenzi MV: Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB. *Oncogene.* 2001 Nov 29;20(55):7965-75.
- \*Rossi D, Gaidano G: Messengers of cell death: apoptotic signaling in health and disease. *Haematologica.* 2003 Feb;88(2):212-8.
- \*Schmidt CS, Liu J, Zhang T, Song HY, Sandusky G, Mintze K, Benschop RJ, Glasebrook A, Yang DD, Na S: Enhanced B cell expansion, survival, and humoral responses by targeting death receptor 6. *J Exp Med.* 2003 Jan 6;197(1):51-62.

**For laboratory research only, not for drug, diagnostic or other use.**